OZEMPIC 0.25mg

Description

OZEMPIC 0.25mg is a once-weekly injectable prescription medicine used to improve blood sugar control in adults with type 2 diabetes mellitus. It contains semaglutide, a GLP-1 receptor agonist that works by enhancing insulin secretion, suppressing glucagon secretion, and slowing gastric emptying. The 0.25 mg dose is typically used as a starting dose for the first four weeks to allow the body to adjust to treatment and reduce gastrointestinal side effects. OZEMPIC® is not insulin and should not be used to treat type 1 diabetes or diabetic ketoacidosis. It is available only with a doctor’s prescription and must be used under medical supervision.

Weekly Dosing: Administered once weekly, regardless of meals or time of day.
GLP-1 Receptor Agonist: Helps the pancreas produce more insulin and lowers glucagon when glucose is high.
Starter Dose: 0.25 mg weekly for four weeks, followed by an increase to 0.5 mg as maintenance or further to 1 mg if necessar

OZEMPIC® 0.25mg is available in a prefilled dial-a-dose pen, which contains 1.5 mL of solution to deliver 0.25 mg or 0.5 mg doses. Each pack includes one pen and six NovoFine® Plus needles. The pen is intended for subcutaneous use and should be used with a new sterile needle for each injection.

Active Ingredient:
Semaglutide (rys): 1.34 mg/mL (Total: 2 mg per pen)
Inactive Ingredients:
Dibasic sodium phosphate dihydrate
Propylene glycol
Phenol
Hydrochloric acid and sodium hydroxide (for pH adjustment)
Water for injections
The abbreviation “rys” indicates recombinant yeast-based production of semaglutide through genetic engineering